Epidémiologie, stratégies thérapeutiques et virologie cliniques dans l'infection à VIH
Accueil
FHDH
A propos de la base
Déjà 20 ans !
DOMEVIH
Principaux résultats
- RICE février 2013
- Publications
L'équipe
- Le GEC
- U1136 (ex-U943)
Collaborations
Etudes cliniques
ONCOVIH
Autres études
EPIDERMAS
FranceCoag
Doctorants - post-docs
EPICLIN 2010

Liste des publications à partir des données
de la base FHDH

2012 2011 2010
2005-2009 2000-2004 1992-1999

2011       104  
Bohlius J, Schmidlin K, Boué F, Fätkenheuer G, May M, Caro-Murillo AM, Mocroft A, Bonnet F, Clifford G, Paparizos V, Miro JM, Obel N, Prins M, Chêne G, Egger M.
-->  HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4+ T cell lymphocytes.
---->  Blood 2011;117:6100-6108.
        105  
Bommenel T, Launay O, Meynard JL, Gilquin J, Katlama C, Lascaux AS, Mahamat A, Martinez V, Pradier C, Rouveix E, Simon A, Costagliola D, Abgrall S on behalf of FHDH-ANRS CO4.
-->  Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a 3-drug regimen containing either efavirenz, nevirapine or abacavir.
---->  J Antimicrob Chemother 2011;66:1869-187.
        106  
Cain LE, Logan R, Robins JM, Sterne JAC, Sabin C, Bansi L, Justice A, Goulet J, van Sighem A, de Wolf F, Bucher HC, von Wyl V, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Lodi S, Lanoy E, Costagliola D, Hernán MA.
-->  When to initiate combined antiretroviral therapy to reduce rates of mortality and AIDS in HIV-infected individuals in developed countries.
---->  Ann Intern Med 2011;154:509-515.
        107  
Castro H, Judd A, Gibb DM, Butler K, Lodwick RK, van Sighem A, Ramos JT, Warsawski J, Thorne C, Noguera-Julian A, Obel N, Costagliola D, Tookey PA, Colin C, Kjaer J, Grarup J, Chene G, Phillips A.
-->  Risk of triple class virologic failure in HIV-infected children.
---->  Lancet 2011; 377:1580-7.
        108  
Jaffe HW, De Stavola BL, Carpenter LM, Porter K, Cox DR; on behalf of the CASCADE Collaboration.
-->  Immune reconstitution and risk of kaposi sarcoma and non-Hodgkin lymphoma in HIV-infected adults.
---->  AIDS 2011;25:1395-403.
        109  
Jonsson Funk M, Fusco JS, Cole SR, Thomas JC, Porter K, Kaufman JS, Davidian M, White AD, Hartmann KE, Eron JJ.
-->  Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters.
---->  Arch Intern Med. 2011;171:1560-1569.
        110  
Lanoy E, Guiguet M, Bentata M, Rouveix E, Dhiver C, Poizot-Martin I, Costagliola D, Gasnault J, on behalf the FHDH-ANRS CO4.
-->  Survival after neuroAIDS: association with antiretroviral CNS penetration-effectiveness score.
---->  Neurology 2011;76:644-651.
        111  
Lanoy E, Rosenberg PS, Fily F, Lascaux AS, Martinez V, Partisani M, Poizot-Martin I, Rouveix E, Engels EA, Costagliola D, Goedert J.
-->  HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy.
---->  Blood 2011;118:44-49.
        112  
Lanoy E, Spano JP, Bonnet F, Guiguet M, Boué F, Cadranel J, Carcelain G, Couderc LJ, Frange P, Girard PM, Oksenhendler E, Poizot-Martin I, Semaille C, Agut A, Katlama C, Costagliola D and the ONCOVIH study group.
-->  The spectrum of malignancies in HIV-infected patients in 2006 in France: the ONCOVIH study.
---->  Int J cancer 2011;129:467-475.
        113  
Lodi S, Phillips A, Touloumi G, Geskus R, Meyer L, Thiébaut R, Pantazis N, Amo JD, Johnson AM, Babiker A, Porter K; on behalf of the CASCADE Collaboration in EuroCoord.
-->  Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds <200, <350, and <500 cells/mm3: assessment of need following changes in treatment guidelines.
---->  Clin Infect Dis 2011;53:817-825.
        114  
Mugavero MJ, May M, Ribaudo HJ, Gulick RM, Riddler SA, Haubrich R, Napravnik S, Abgrall S, Phillips A, Harris R, Gill MJ, de Wolf F, Hogg R, Günthard HF, Chêne G, Dʼarminio Monforte A, Guest JL, Smith C, Murillas J, Berenguer J, Wyen C, Domingo P, Kitahata MM, Sterne JA, Saag MS.
-->  Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study.
---->  J Acquir Immune Defic Syndr 2011;58:253-60.
        115  
Mussini C, Cossarizza A, Sabin C, Babiker A, De Luca A, Bucher HC, Fisher M, Rezza G, Porter K, Dorrucci M; on behalf of CASCADE Collaboration.
-->  Decline of CD4+ T-cell count before start of therapy and immunological response to treatment in antiretroviral-naive individuals.
---->  AIDS 2011;25:1041-1049.
        116  
Van der Helm JJ, Prins M, Del Amo J, Bucher HC, Chêne G, Dorrucci M, Gill J, Hamouda O, Sannes M, Porter K, Geskus RB; on behalf of the CASCADE Collaboration.
-->  The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007.
---->  AIDS 2011;25:1083-1091.
Adresse Mentions légales Extranet Administration